Everest Medicines Reports Nefecon's Approval In China; Triggers Milestone Payment To Calliditas

(RTTNews) - Calliditas Therapeutics AB (CALT) said its partner Everest Medicines announced that China's National Medical Products Administration has approved Nefecon for the treatment of primary immunoglobulin A nephropathy in adults at risk of disease progression. The approval triggers a milestone payment of $5 million to Calliditas, which will be included as revenue in the fourth quarter.

Everest Medicines also announced that, in addition to Nefecon's approval in mainland China and Macau, it expects a decision on New Drug Application approval in Singapore and Hong Kong in the near term.

For More Such Health News, visit rttnews.com.